{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=16", "query": { "intervention": "therapy", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 83820, "total_pages": 8382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T22:47:57.828Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02862275", "title": "Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-05-24", "completion_date": "2026-11-21", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 8, "location_summary": "La Jolla, California • Tampa, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02862275" }, { "nct_id": "NCT02433457", "title": "Relative Bioavailability Study of CC-292", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "CC-292", "type": "DRUG" }, { "name": "Oral Omeprazole (OMP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2014-05-26", "completion_date": "2014-09-26", "has_results": false, "last_update_posted_date": "2020-08-13", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02433457" }, { "nct_id": "NCT02186457", "title": "Antibiotic Irrigation for Pancreatoduodenectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Surgery", "Infection" ], "interventions": [ { "name": "Polymyxin B in Normal Saline", "type": "DRUG" }, { "name": "Placebo: Normal Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "88 Years", "sex": "ALL", "summary": "18 Years to 88 Years" }, "enrollment_count": 190, "start_date": "2014-11", "completion_date": "2019-08", "has_results": true, "last_update_posted_date": "2022-02-23", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02186457" }, { "nct_id": "NCT07391657", "title": "A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 508, "start_date": "2026-02-23", "completion_date": "2030-07-29", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 48, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07391657" }, { "nct_id": "NCT07469501", "title": "Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Opioid Use Disorder", "Fentanyl" ], "interventions": [ { "name": "Injectable buprenorphine", "type": "DRUG" }, { "name": "Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-06", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07469501" }, { "nct_id": "NCT00067301", "title": "PUFA Augmentation in Treatment of Major Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depression" ], "interventions": [ { "name": "Polyunsaturated Fatty Acids (PUFA)", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Center for Complementary and Integrative Health (NCCIH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2003-09", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2008-01-25", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067301" }, { "nct_id": "NCT06480201", "title": "Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Major Depressive Disorder", "Treatment Resistant Depression" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Texas A&M University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "21 Years to 45 Years" }, "enrollment_count": 100, "start_date": "2024-01-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06480201" }, { "nct_id": "NCT02121301", "title": "A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Keratoconjunctivitis Sicca" ], "interventions": [ { "name": "Low Dose 0.155µg/mL SkQ1 ophthalmic solution", "type": "DRUG" }, { "name": "High Dose 1.55µg/mL SkQ1 ophthalmic solution", "type": "DRUG" }, { "name": "Placebo (Vehicle) opthalmic solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mitotech, SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2014-04", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2020-11-02", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02121301" }, { "nct_id": "NCT03515512", "title": "IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-07-17", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515512" }, { "nct_id": "NCT00573612", "title": "Exercise-based Motivational Interviewing for Fibromyalgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fibromyalgia" ], "interventions": [ { "name": "Attention Control Counseling", "type": "BEHAVIORAL" }, { "name": "Motivational Interviewing", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 200, "start_date": "2007-12", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-04-06", "last_synced_at": "2026-10-20T22:47:57.828Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573612" } ] }